首页> 外文期刊>Cell biology international. >Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays.
【24h】

Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays.

机译:使用多种测定法研究人胶质母细胞瘤细胞U138MG的化学抗性CD133 +癌症干细胞。

获取原文
获取原文并翻译 | 示例
       

摘要

Glioblastoma is one of the most common malignant tumours in adults, with an average life expectancy of less than 1 year. The high mortality of glioblastomas is attributed to its resistance to conventional chemotherapeutic agents. Numerous studies have established the presence of a cancer stem population within glioblastomas. These CSC (cancer stem cell) populations express the cell-surface marker, CD133, and are tumorigenic and chemoresistant. Hence, CSCs make a potential target for anticancer therapies. We have focused on techniques that can reliably identify and isolate a viable CSC population, and studied their chemoresistant attributes. We show the presence of a CSC population within a slowly proliferating glioblastoma cell line, U138MG. An improvised neurosphere enrichment culture technique was developed for the isolation of CSC population. Stem cell neurospheres obtained by this protocol maintained their viability for several weeks, and could be redispersed for deriving colony-forming units and secondary spheres from single-cell suspensions. RT-PCR (reverse transcription-PCR), cell surface localization by immunofluorescence and enumeration by FACS analysis showed that the sphere cultures of U138MG grown on agarose-coated plates had elevated CD133 levels. Drug sensitivity assays indicated that these enriched spheres were more resistant to drug treatment than their non-CSC controls. Drug-resistant CSC had an increased expression of ABC (ATP-binding-cassette) drug transporters, such as ABCC2, ABCC4, ABCG2 and p-glycoprotein, indicative of their role in the resistance mechanisms. These studies will facilitate the development of in vitro assays for the sparse CSC population and strategies for improved treatment regimens for glioblastomas.
机译:胶质母细胞瘤是成人中最常见的恶性肿瘤之一,平均寿命不到一年。胶质母细胞瘤的高死亡率归因于其对常规化学治疗剂的抗性。大量研究已经确定胶质母细胞瘤中存在癌症干群。这些CSC(癌症干细胞)种群表达细胞表面标记CD133,并且具有致瘤性和化学抗性。因此,CSCs成为抗癌治疗的潜在目标。我们专注于可以可靠地识别和隔离可行的CSC种群的技术,并研究了其化学抗性。我们显示在缓慢增殖的胶质母细胞瘤细胞系U138MG中存在CSC群体。开发了一种简易的神经球富集培养技术来分离CSC种群。通过该协议获得的干细胞神经球保持了数周的生存能力,可以重新分散以从单细胞悬液中获得集落形成单位和次级球。 RT-PCR(逆转录PCR),通过免疫荧光进行的细胞表面定位以及通过FACS分析进行的计数显示,在琼脂糖包被的板上生长的U138MG球形培养物具有升高的CD133水平。药物敏感性分析表明,这些富集的球体比其非CSC对照对药物治疗的抵抗力更高。耐药的CSC的ABC(ATP结合盒式)药物转运蛋白,例如ABCC2,ABCC4,ABCG2和p-糖蛋白的表达增加,表明它们在耐药机制中的作用。这些研究将促进针对稀疏CSC人群的体外测定方法的开发,以及改善胶质母细胞瘤治疗方案的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号